Navigation Links
CalciMedica Announces Issuance of US Patent No. 7,645,588, a Composition Patent Involving STIM1, a Key Component of the CRAC Channel
Date:2/16/2010

LA JOLLA, Calif., Feb. 16 /PRNewswire/ -- CalciMedica today announced that the US Patent and Trademark Office has issued to CalciMedica US Patent No. 7,645,588, a composition patent involving STIM1, a key component of the calcium release-activated calcium (CRAC) channel. The patent, entitled "Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use," has a priority date of March 4, 2003 and was issued on January 12, 2010. The compositions covered by the patent include both a recombinant cell expressing the STIM1 protein and an agent that reduces calcium ion stores in the cell.

The CRAC channel is the gatekeeper for the Icrac-NFAT pathway, a network essential for the adaptive immune response. STIM1, a calcium sensor in the endoplasmic reticulum, interacts with Orai1, the CRAC channel subunit in the plasma membrane, to regulate calcium entry into T cells. The composition of matter claims can be used for multiple purposes, including assays for the discovery of agents that modulate the activity of CRAC channels. These agents, in turn, can be developed for the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis, multiple sclerosis, ulcerative colitis as well as organ transplant rejection and other diseases of the immune system, such as allergy and asthma.

"Establishing patent protection of the STIM1 technology, a key component of our drug discovery platform, is an important achievement for CalciMedica," said Gonul Velicelebi, PhD, Chief Executive Officer of CalciMedica and co-inventor on the patent. "We have made great strides in using this technology to identify novel small molecule CRAC channel inhibitors and validating the potential of the CRAC channel as a therapeutic target. We are advancing to investigational new drug (IND) status with our lead molecule, an oral, selective CRAC channel inhibitor with in vivo efficacy in animal models of inflammation, and we look forward to realizing our goal of bringing this first-in-class drug into clinical development."

About CalciMedica, Inc.

CalciMedica is dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune and inflammatory diseases. The primary focus of the company's drug discovery effort is based on the specific inhibition of calcium release-activated calcium (CRAC) channels, a key component of the Icrac-NFAT pathway. The Icrac-NFAT calcium entry pathway is essential for the adaptive immune response, and has been clinically validated as an important drug target in humans through the use of calcineurin inhibitors. The CRAC channel is the gatekeeper for this pathway, and based on the phenotype of SCID patients with loss-of-function mutation in Orai1, it is predicted that selective inhibition of CRAC channels should be effective and safe for chronic immunomodulation. CalciMedica has acquired exclusive rights to both STIM1 and Orai1 which act synergistically to regulate CRAC channel activity. CalciMedica has discovered novel potent and selective CRAC channel inhibitors with good in vivo efficacy and pharmaceutical properties and is advancing the lead molecule to an investigational new drug (IND) filing. CalciMedica is located in La Jolla, California. 

SOURCE CalciMedica, Inc.

RELATED LINKS
http://www.calcimedica.com

'/>"/>

SOURCE CalciMedica, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2017)... June 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that the U.S. Food and Drug Administration (FDA) has ... 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter related ... facility is a measure of the progress we have made ...
(Date:6/11/2017)... and Company (NYSE: LLY ) announced today ... an investigational treatment for the prevention of episodic and ... endpoints for galcanezumab compared to placebo at both studied ... REGAIN) will be presented today at the American Headache ... . "The detailed Phase 3 ...
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... June 24, 2017 , ... ... at the Sheraton Erie Bayfront and Erie Convention Center on June 8-10. ... exhibits, a student quiz bowl, award and scholarship presentations, and professional networking. ...
(Date:6/23/2017)... ... 23, 2017 , ... The Rhode Island Quality Institute (RIQI) ... and Dashboards, an innovative new service enabling healthcare providers to proactively coordinate care ... and Dashboards provide near real-time data about patients admitted to and/or discharged from ...
(Date:6/23/2017)... (PRWEB) , ... June 24, 2017 , ... Studies show ... significantly reduce the risk of visual loss in these patients. , But how often ... diet, or smoking cessation to patients at risk of or with early symptoms of ...
(Date:6/23/2017)... ... ... Everybody has their own personal preference when it comes to pornography. Some ... don't like it at all. FindaTopDoc took a look at what makes people attracted ... readers a taste of their deepest, darkest fantasies and has the ability to help ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Cancer Conference from Sept. 18 to 20. , The two-day conference is focused ... with the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. ...
Breaking Medicine News(10 mins):